Pure Global
NCT05513729

Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Therapeutic Effects of Canagliflozin on the Liver Inflammation Damage and Lipoprotein Metabolism in Patients With Type 2 Diabetes Mellitus Combined With Nonalcoholic Fatty Liver Disease
First Affiliated Hospital Xi'an Jiaotong University·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 2 Diabetes Mellitus With Complication
Drug/Device/Intervention
Canagliflozin
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
First Affiliated Hospital Xi'an Jiaotong University
Location
Xi'an, China
Timeline & enrollment
Phase
N/A
Start date
Aug 18, 2022
End date
Mar 01, 2024
Enrollment
80 participants
Primary outcome

Plasma cholesteryl ester transfer protein(CETP) concentration(ug/mL),The activity of CEPT in pmol/mL/min

Summary

Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease
 (NAFLD).This prospective study was designed to reveal the potential clinical application and
 underlying mechanisms of canagliflozin in the treatment of type 2 diabetes combined with
 nonalcoholic fatty liver disease.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with multiple complicationsType 2 diabetes mellitus without complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05513729
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05513729 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital Xi'an Jiaotong University and is currently Recruiting. The study focuses on Type 2 Diabetes Mellitus With Complication. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.